export default function TirzepatideOverviewPanel() {
  return (
    <div className="reta-overview">

      <p className="reta-overview__opener">
        Tirzepatide (Mounjaro for diabetes, Zepbound for weight loss) is the most effective weight loss drug currently available. In the SURMOUNT-1 trial, people taking the highest dose lost an average of 22% of their body weight — one-third of participants lost over 25%, crossing into territory previously only seen with bariatric surgery. It works by hitting two pathways simultaneously instead of one, and most people find it causes less nausea than semaglutide at comparable clinical effect.
      </p>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 1</div>
        <h3 className="reta-overview__profile-heading">The Average Person &mdash; Serious About Weight Loss</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;I&rsquo;ve tried everything. My doctor mentioned tirzepatide or semaglutide. How do I know which one is actually better for me and whether the weight loss sticks?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re excited</p>
        <ol className="reta-overview__profile-why">
          <li><strong>The weight loss numbers are genuinely impressive</strong><br />An average of 22% body weight reduction in 72 weeks is not marketing language — it&rsquo;s what the controlled trial data showed. For someone who has spent years unable to lose significant weight through diet and exercise, that number represents a real change in what&rsquo;s medically achievable. A third of participants in SURMOUNT-1 lost over 25%, which is bariatric surgery territory.</li>
          <li><strong>Most people tolerate it better than semaglutide</strong><br />The drug hits two appetite-related pathways instead of one, and the second pathway appears to reduce the nausea that makes semaglutide difficult for many people. That tolerability difference is mechanistically explainable — not just anecdotal from community forums — and it matters for people who tried semaglutide and had to stop.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">The weight comes back when you stop. SURMOUNT-4 data showed about 14% weight regain within a year of discontinuing tirzepatide — essentially the same cessation rebound as semaglutide. This is a medication most people who respond well will need to take long-term, not a course you complete and walk away from. It&rsquo;s also newer than semaglutide, meaning the post-market real-world safety record is shorter. And the same contraindications apply — personal or family history of thyroid C-cell tumors or a syndrome called MEN2 is a hard stop. Net: the most effective approved weight loss drug available, but it works as long as you take it.</p>
      </div>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 2</div>
        <h3 className="reta-overview__profile-heading">The Athlete &mdash; Body Recomposition Without Losing Muscle</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;I want to drop body fat without sacrificing the muscle I&rsquo;ve built. Can tirzepatide help with recomposition, and what do I need to do to protect lean mass while I&rsquo;m on it?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re excited</p>
        <ol className="reta-overview__profile-why">
          <li><strong>The degree of fat loss is unmatched by any other pharmacological tool</strong><br />For an athlete who has reached the limits of what diet and training manipulation can do for body composition, tirzepatide&rsquo;s 20%+ body weight effect represents a fundamentally different level of fat loss than anything else available. Even getting from 15% body fat to 10% — which is brutally difficult through training alone — is within reach on this drug if used carefully.</li>
          <li><strong>Second-pathway activation reduces caloric intake without maximizing nausea</strong><br />Tirzepatide works partly by making food less rewarding and partly by slowing gastric emptying. Athletes who&rsquo;ve tried semaglutide and found it too limiting for training nutrition often report tirzepatide more manageable — the GIP component appears to attenuate the nausea that makes eating enough protein difficult on semaglutide.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">The appetite suppression is so powerful that many people on tirzepatide eat so little that lean mass loss becomes a serious concern. This is not hypothetical — the SURMOUNT trials did not require resistance training, and some participants likely lost significant muscle alongside fat. For athletes, deliberate protein anchoring (prioritizing protein intake even when appetite is suppressed) and resistance training are non-optional, not suggestions. The titration schedule from 2.5mg up to 15mg takes 20 weeks — rushing it produces nausea that derails training. Net: the most powerful body recomposition tool available pharmacologically, but the muscle protection work is entirely on you.</p>
      </div>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 3</div>
        <h3 className="reta-overview__profile-heading">The Biohacker &mdash; Metabolic Longevity and the Dual Agonism Advantage</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;Metabolic health is the core of longevity. Tirzepatide hits two receptors simultaneously. What does the dual mechanism actually add beyond semaglutide, and what do the cardiovascular outcome data gaps mean?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re excited</p>
        <ol className="reta-overview__profile-why">
          <li><strong>The second receptor adds a direct adipose tissue effect</strong><br />Semaglutide works primarily through appetite and satiety signaling. Tirzepatide adds a second pathway that acts directly on fat tissue — affecting how fat cells store and release energy. That direct adipose effect helps explain why tirzepatide produces more fat loss at lower nausea cost: two synchronized mechanisms, not just a stronger version of one.</li>
          <li><strong>The metabolic improvements go beyond body weight</strong><br />In the SURPASS-2 trial, tirzepatide produced superior blood sugar control compared to semaglutide. The insulin sensitivity improvements, visceral fat reduction, and lipid profile changes that accompany significant weight loss on tirzepatide represent a comprehensive metabolic reset — not just a number on the scale.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">Tirzepatide is meaningfully newer than semaglutide — the post-market safety record is shorter, and the cardiovascular outcome trial (SURPASS-CVOT) is still ongoing. Semaglutide has the SELECT trial showing cardiovascular benefit in people with obesity; tirzepatide does not yet have equivalent data. For someone optimizing metabolic longevity, that evidence gap matters — semaglutide&rsquo;s cardiovascular benefits are proven and tirzepatide&rsquo;s are inferred from metabolic improvements. The drug also works only while taken — sustained metabolic benefit requires sustained treatment. Net: the most powerful metabolic tool currently approved, with a developing long-term evidence base that hasn&rsquo;t yet caught up to semaglutide&rsquo;s.</p>
      </div>

      <div className="reta-overview__bottom">
        <p className="reta-overview__bottom-heading">The honest bottom line</p>
        <div className="reta-overview__bottom-cols">
          <div className="reta-overview__bottom-col">
            <p className="reta-overview__bottom-col-heading">What Tirzepatide is NOT</p>
            <ul className="reta-overview__bottom-list">
              <li>A permanent fix — weight returns when the drug stops, which is why most people who respond well take it long-term</li>
              <li>Safe without muscle protection strategies — severe appetite suppression without resistance training causes lean mass loss</li>
              <li>Proven for cardiovascular benefit yet — the outcome trial is ongoing; semaglutide has SELECT data, tirzepatide doesn&rsquo;t yet</li>
              <li>Appropriate with a history of thyroid C-cell tumors or MEN2 syndrome — class-level contraindication shared with semaglutide</li>
              <li>A replacement for lifestyle change — people who resist training and high protein intake lose more muscle and see worse long-term outcomes</li>
            </ul>
          </div>
          <div className="reta-overview__bottom-col">
            <p className="reta-overview__bottom-col-heading">What makes it interesting</p>
            <ul className="reta-overview__bottom-list">
              <li>The most effective approved weight loss drug — 22% average body weight reduction, one-third of users lost 25%+</li>
              <li>Better nausea tolerance than semaglutide at comparable clinical effect — mechanistically explainable, not just anecdotal</li>
              <li>FDA-approved for both T2D (Mounjaro) and obesity (Zepbound) — legitimate prescription access exists</li>
              <li>Superior blood sugar control to semaglutide in head-to-head trial data (SURPASS-2)</li>
              <li>The dual mechanism targets appetite and fat tissue through separate synchronized pathways</li>
            </ul>
          </div>
        </div>
      </div>

    </div>
  );
}
